HAO vs LFS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HAO presents as a classic value trap, characterized by a stable Piotroski F-Score of 6/9 and a Graham Number of $13.09 that vastly exceeds the current price of $1.07. While valuation metrics like the P/E (0.84) and Price/Book (0.18) suggest extreme undervaluation, these are offset by a catastrophic YoY revenue decline of 64.60%. The disconnect between a positive net profit margin (11.82%) and a negative operating margin (-21.16%) suggests that earnings are likely driven by non-operating items rather than core business health. Combined with a 0/100 technical trend and long-term price collapse, the fundamental business decay outweighs the theoretical value.
LFS presents a high-risk profile characterized by a stable Piotroski F-Score of 5/9, but severe valuation misalignment. The stock is trading at $2.07, representing a significant premium over its Graham Number ($0.90) and Intrinsic Value ($0.77). Despite modest revenue growth of 15.9%, the company is experiencing earnings contraction (-5.00% YoY) and a catastrophic technical collapse, losing over 50% of its value in the last six months.
Compare Another Pair
Related Comparisons
HAO vs LFS: Head-to-Head Comparison
This page compares Haoxi Health Technology Limited (HAO) and Leifras Co., Ltd. (LFS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.